Skip to main content
. 2024 Apr 23;134(11):e161660. doi: 10.1172/JCI161660

Figure 5. CV1-Fc-engineered T cells are phagocytosed by macrophages in vitro and depleted in vivo.

Figure 5

(A) Schematic of ACT against subcutaneous A375 tumors and ex vivo analysis. (B) A375 tumor growth and control curves following ACT (n = 7). (C) Frequency and number of human CD45+ cells in harvested tissues 5 days after ACT (n ≥4; data are representative of 2 independent studies). (D) A375 tumor growth and control curves following ACT supplemented with coadministration of soluble inSiRPα-Fc and CV1-Fc proteins (n ≥5). (E) Flow cytometry detection of T cell–secreted CV1-Fc binding on T cell surface CD47 by anti–human IgG-Fc Ab staining (data are representative of 6 donors). (F) Phagocytosis of T cells coated with secreted CV1-Fc by NSG BMDMs in vitro (n = 3). (G) Phagocytosis of T cells coated with secreted CV1-Fc by MDMs in vitro (n = 7). Statistical analysis was done by 2-way ANOVA (B and D), 1-way ANOVA (C), or unpaired 2-tailed t test (F and G) with correction for multiple comparisons by post hoc Tukey’s test (B–D). *P < 0.05; **P < 0.01; ***P < 0.001; ****P< 0.0001.